Loading...

KKR's Entry Will Enable Expansion Of Precision Oncology And Fertility Services

Published
24 Jan 25
Updated
28 Aug 25
AnalystConsensusTarget's Fair Value
₹676.71
2.6% overvalued intrinsic discount
28 Aug
₹694.25
Loading
1Y
73.7%
7D
1.2%

Author's Valuation

₹676.7

2.6% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on04 Aug 25
Fair value Increased 19%

The modest increases in both net profit margin and future P/E suggest improved profitability and sustained growth expectations for HealthCare Global Enterprises, supporting the upward revision of the consensus analyst price target from ₹567.29 to ₹603.88. What's in the News KKR Asian Fund IV SCSp, managed by KKR & Co. Inc., and KIA EBT II Scheme 1 completed the acquisition of a 50.4% stake in HealthCare Global Enterprises Limited from Aceso Company Pte Ltd for INR 34.28 billion, with regulatory approvals secured.

Shared on01 May 25
Fair value Increased 1.11%

Shared on23 Apr 25
Fair value Increased 2.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.79%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 7.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Decreased 0.72%